» Articles » PMID: 8610103

Immunohistochemical Detection of 4-hydroxynonenal Protein Adducts in Parkinson Disease

Overview
Specialty Science
Date 1996 Apr 2
PMID 8610103
Citations 300
Authors
Affiliations
Soon will be listed here.
Abstract

There is growing evidence that oxidative stress and mitochondrial respiratory failure with attendant decrease in energy output are implicated in nigral neuronal death in Parkinson disease (PD). It is not known, however, which cellular elements (neurons or glial cells) are major targets of oxygen-mediated damage. 4-Hydroxy-2-nonenal (HNE) was shown earlier to react with proteins to form stable adducts that can be used as markers of oxidative stress-induced cellular damage. We report here results of immunochemical studies using polyclonal antibodies directed against HNE-protein conjugates to label the site of oxidative damage in control subjects (ages 18-99 years) and seven patients that died of PD (ages 57-78 years). All the nigral melanized neurons in one of the midbrain sections were counted and classified into three groups according to the intensity of immunostaining for HNE-modified proteins--i.e., no staining, weak staining, and intensely positive staining. On average, 58% of nigral neurons were positively stained for HNE-modified proteins in PD; in contrast only 9% of nigral neurons were positive in the control subjects; the difference was statistically significant (Mann-Whitney U test; P < 0.01). In contrast to the substantia nigra, the oculomotor neurons in the same midbrain sections showed no or only weak staining for HNE-modified proteins in both PD and control subjects; young control subjects did not show any immunostaining; however, aged control subjects showed weak staining in the oculomotor nucleus, suggesting age-related accumulation of HNE-modified proteins in the neuron. Our results indicate the presence of oxidative stress within nigral neurons in PD, and this oxidative stress may contribute to nigral cell death.

Citing Articles

Targeting the Interplay Between Autophagy and the Nrf2 Pathway in Parkinson's Disease with Potential Therapeutic Implications.

Liu M, Liu S, Lin Z, Chen X, Jiao Q, Du X Biomolecules. 2025; 15(1).

PMID: 39858542 PMC: 11764135. DOI: 10.3390/biom15010149.


Genetic mutations in kinases: a comprehensive review on marketed inhibitors and unexplored targets in Parkinson's disease.

Raza A, Raina J, Sahu S, Wadhwa P Neurol Sci. 2025; .

PMID: 39760821 DOI: 10.1007/s10072-024-07970-2.


The Role of ETNPPL in Dopaminergic Neuron Stability: Insights from Neuromelanin-Associated Protein Expression in Parkinson's Disease.

Schillaci F, Lanza G, Salluzzo M, LEpiscopo F, Ferri R, Salemi M Int J Mol Sci. 2024; 25(23).

PMID: 39684817 PMC: 11642302. DOI: 10.3390/ijms252313107.


Mitochondrial dysfunction in Parkinson's disease.

Hattori N, Sato S J Neural Transm (Vienna). 2024; 131(12):1415-1428.

PMID: 39585446 DOI: 10.1007/s00702-024-02863-2.


Targeting ferroptosis with the lipoxygenase inhibitor PTC-041 as a therapeutic strategy for the treatment of Parkinson's disease.

Minnella A, McCusker K, Amagata A, Trias B, Weetall M, Latham J PLoS One. 2024; 19(9):e0309893.

PMID: 39292705 PMC: 11410249. DOI: 10.1371/journal.pone.0309893.


References
1.
Hattori N, Tanaka M, Ozawa T, Mizuno Y . Immunohistochemical studies on complexes I, II, III, and IV of mitochondria in Parkinson's disease. Ann Neurol. 1991; 30(4):563-71. DOI: 10.1002/ana.410300409. View

2.
Smith C, Carney J, Oliver C, Stadtman E, Floyd R, Markesbery W . Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc Natl Acad Sci U S A. 1991; 88(23):10540-3. PMC: 52964. DOI: 10.1073/pnas.88.23.10540. View

3.
Jellinger K, Kienzl E, Rumpelmair G, Riederer P, Stachelberger H, Ben-Shachar D . Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis. J Neurochem. 1992; 59(3):1168-71. DOI: 10.1111/j.1471-4159.1992.tb08362.x. View

4.
Jenner P, Dexter D, Sian J, Schapira A, Marsden C . Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group. Ann Neurol. 1992; 32 Suppl:S82-7. DOI: 10.1002/ana.410320714. View

5.
Hirsch E . Why are nigral catecholaminergic neurons more vulnerable than other cells in Parkinson's disease?. Ann Neurol. 1992; 32 Suppl:S88-93. DOI: 10.1002/ana.410320715. View